REUTERS/Mike Blake/File PhotoWASHINGTON, June 5 (Reuters) - Illumina (ILMN.O) on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest cancer diagnostic test maker Grail (GRAL.O) over competition concerns in the U.S. market for cancer tests.
San Diego-based Illumina is arguing that the FTC "violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal," according to the filing in the U.S. Fifth Circuit Court of Appeals.
An administrative law judge at the FTC had earlier dismissed the antitrust charges brought against Illumina but FTC staff won an appeal against that decision.
In early December, EU antitrust regulators proposed measures for Illumina to unwind its acquisition of Grail, three months after blocking the deal.
Billionaire investor Carl Icahn, who owns 1.4% of the company, had also urged Illumina to unwind the Grail deal which he called a risky acquisition.
Persons:
Mike Blake, Illumina, Carl Icahn, Francis deSouza, Vincent Intrieri, Diane Bartz, Mrinmay Dey, Jamie Freed, Edwina Gibbs
Organizations:
REUTERS, WASHINGTON, Federal Trade Commission, Fifth, Appeals, FTC, Illumina, Thomson
Locations:
San Diego , California, U.S, Diego, Europe, EU